Advertisement

Topics

Twin lampalizumab trials fail to impact area of geographic atrophy

13:00 EST 11 Nov 2017 | Healio

Jeffrey S. Heier
NEW ORLEANS — Lampalizumab failed to impact geographic area compared with sham treatment in two identically designed phase 3 studies — Chroma and Spectri, according to a speaker.
Giving 48-week topline results of the Spectri trial of lampalizumab at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting, Jeffrey S. Heier, MD, said, “Lampalizumab did not reduce GA area change from baseline. The primary endpoint was not met. Lampalizumab was not effective in reducing GA lesion growth. Chroma also demonstrated no treatment benefit of

Original Article: Twin lampalizumab trials fail to impact area of geographic atrophy

NEXT ARTICLE

More From BioPortfolio on "Twin lampalizumab trials fail to impact area of geographic atrophy"

Advertisement
Quick Search
Advertisement
Advertisement